Panlong Pharmaceutical announced that director Zhu Wenfeng reduced his holdings of the company's shares by 22,500 shares through centralized bidding on March 12, 2026, at an average reduction price of 33.49 yuan/share, representing a reduction ratio of 0.0212%. Before the reduction, he held 90,000 shares, and after the reduction, he holds 67,500 shares, accounting for 0.0637%. The reduction plan has been completed